FDA approval of Bizengri gives Partner Therapeutics a broader rare-oncology opportunity
Rare cancer biology met regulatory urgency. Bizengri’s approval tests whether precision oncology can reach tiny patient subsets fast.
Why Partner Therapeutics’ BIZENGRI approval matters beyond cholangiocarcinoma
Rare cancer biology is becoming commercially actionable. BIZENGRI’s FDA approval puts NRG1 fusion testing under sharper scrutiny.
Partner Therapeutics’ zenocutuzumab data adds nuance to progression-driven treatment decisions in NRG1-positive lung cancer
Find out how zenocutuzumab treatment beyond progression could change care for NRG1 fusion-positive lung cancer and what clinicians should watch next.
Treatment beyond progression? Zenocutuzumab data could shift standards in NRG1+ pancreatic cancer
Find out how zenocutuzumab could change treatment strategies in NRG1+ pancreatic cancer after progression. Explore new ASCO GI 2026 data today.